-
Firdapse Oral Therapy Expected to Become LEMS’ Treatment of Choice, Review Says
Scientists believe Firdapse (amifampridine phosphate) will soon become first-line management therapy for Lambert-Eaton myasthenic syndrome. Read more here.
What do you think of this prediction?
Sorry, there were no replies found.
Log in to reply.